Want to see IN:CONCORDBIO full AI Analyst Report?
Concord Biotech Ltd. (CONCORDBIO) Income Statement
Concord Biotech Ltd. Income Statement
Last quarter (Q1 2027), Concord Biotech Ltd.'s total revenue was $2.57B, an increase of 26.23% from the same quarter last year. In Q1, Concord Biotech Ltd.'s net income was $585.26M. See Concord Biotech Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| $ 10.55B | $ 12.00B | $ 10.17B | $ 8.53B | $ 7.13B | |
| $ 4.42B | $ 7.68B | $ 6.67B | $ 6.61B | $ 5.41B | |
| $ 1.49B | $ 1.66B | $ 1.46B | $ 1.43B | $ 1.25B | |
| Depreciation and Amortization | $ 744.59M | $ 543.74M | $ 535.91M | $ 540.32M | $ 500.50M |
| $ 4.19B | $ 5.14B | $ 4.40B | $ 3.54B | $ 2.79B | |
| $ 2.93B | $ 6.02B | $ 5.21B | $ 5.18B | $ 4.16B | |
| $ 517.06M | $ -1.07B | $ -1.09B | $ -1.96B | $ -1.79B | |
| $ 3.45B | $ 4.95B | $ 4.13B | $ 3.22B | $ 2.38B | |
| $ 2.61B | $ 3.72B | $ 3.08B | $ 2.40B | $ 1.75B | |
| Per Share Metrics | |||||
| Basic EPS | $ 24.78 | $ 35.52 | $ 29.45 | $ 22.95 | $ 16.72 |
| Diluted EPS | $ 24.78 | $ 35.52 | $ 29.45 | $ 22.95 | $ 16.72 |
| Weighted Average Shares Outstanding | 105.29M | 104.62M | 104.62M | 104.62M | 104.62M |
| Weighted Average Shares Outstanding (Diluted) | 105.29M | 104.62M | 104.62M | 104.62M | 104.62M |
Currency in INR
